Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

NCT07237256 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3902

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Chemotherapy followed by endocrine therapy and ribociclib treatment
OTHER: De-escalation

Sponsor

UNICANCER

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]